Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

Viking Therapeutics, Inc (VKTX)

Pharmaceutical Preparations

https://www.vikingtherapeutics.com

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/29/2015

Market Cap

6,229,505,100

Shares Outstanding

100,030,000

Weighted SO

100,028,953

Total Employees

N/A

Upcoming Earnings

10/23/2024

Similar Tickers

ICPT --.--%

TERN --.--%

AKRO --.--%

RETA --.--%

MDGL --.--%

SRPT --.--%

HEPA --.--%

PTCT --.--%

AXSM --.--%

Beta

1.0240

Last Div

0.0000

Range

8.28-99.41

Chg

-0.7750

Avg Vol

3804735

Mkt Cap

6229505100

Exch

NASDAQ

Country

US

Phone

858 704 4660

DCF Diff

55.7799

DCF

0.5751

Div Yield

0.0000

P/S

14287.8557

EV Multiple

-49.7107

P/FV

6.7392

Div Yield %

0.0000

P/E

-64.1551

PEG

18.8188

Payout

0.0000

Current Ratio

37.6888

Quick Ratio

37.6888

Cash Ratio

1.7501

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

13675.1689

CCC

-13675.1689

Gross Margin

0.3211

Op Margin

-285.9564

Pretax Margin

-221.8922

Net Margin

-221.8922

Eff Tax Rate

-0.0115

ROA

-0.1022

ROE

-0.1505

ROCE

-0.1353

NI/EBT

1.0000

EBT/EBIT

0.7760

EBIT/Rev

-285.9564

Debt Ratio

0.0012

D/E

0.0012

LT Debt/Cap

0.0008

Total Debt/Cap

0.0012

Int Coverage

-4452.7500

CF/Debt

-65.4045

Equity Multi

1.0281

Rec Turnover

0.0000

Pay Turnover

0.0267

Inv Turnover

0.0000

FA Turnover

0.4463

Asset Turnover

0.0005

OCF/Share

-0.6517

FCF/Share

-0.6517

Cash/Share

8.5358

OCF/Sales

-165.0115

FCF/OCF

1.0000

CF Coverage

-65.4045

ST Coverage

-215.4042

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

6.7392

P/B

6.7392

P/S

14287.8557

P/E

-64.1551

P/FCF

-86.5870

P/OCF

-86.2699

P/CF

-86.2699

PEG

18.8188

P/S

14287.8557

EV Multiple

-49.7107

P/FV

6.7392

DPS

0.0000

Latest Headlines (EST)

The Motley Fool May 16, 21:20 Why Viking Therapeutics Stock Bumped 3% Higher Today The Motley Fool Feb 11, 00:13 Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today The Motley Fool Dec 20, 23:32 Why Viking Therapeutics Tumbled by More Than 10% This Week The Motley Fool Nov 17, 12:05 Is It Too Late to Buy Viking Therapeutics Stock? The Motley Fool Oct 27, 14:45 Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution? The Motley Fool Oct 13, 16:11 Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics The Motley Fool Sep 30, 22:34 Why Viking Therapeutics Stock Topped the Market Today The Motley Fool Sep 20, 22:14 Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today The Motley Fool Sep 12, 23:12 Why Investors Plowed Into Viking Therapeutics Stock Today The Motley Fool Jul 25, 23:06 Why Weight Loss Drug Developer Stocks Tumbled on Thursday The Motley Fool May 17, 13:00 Is Viking Therapeutics Stock a Buy? The Motley Fool May 17, 13:00 Is Viking Therapeutics Stock a Buy? The Motley Fool May 17, 13:00 Is Viking Therapeutics Stock a Buy? The Motley Fool May 17, 13:00 Is Viking Therapeutics Stock a Buy? The Motley Fool May 17, 13:00 Is Viking Therapeutics Stock a Buy? The Motley Fool Jan 22, 01:29 2 Stocks That Could Soar This Year: Are They Buys? The Motley Fool Jan 22, 01:29 2 Stocks That Could Soar This Year: Are They Buys? MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk? 

Revenue Product Segmentation